S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Laser breakthrough could send stock soaring 2,467% (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Laser breakthrough could send stock soaring 2,467% (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Laser breakthrough could send stock soaring 2,467% (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Laser breakthrough could send stock soaring 2,467% (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
NASDAQ:ATOS

Atossa Therapeutics (ATOS) Price Target & Analyst Ratings

$0.71
-0.02 (-2.72%)
(As of 10/2/2023 ET)
Compare
Today's Range
$0.68
$0.74
50-Day Range
$0.71
$1.11
52-Week Range
$0.50
$1.39
Volume
381,474 shs
Average Volume
611,560 shs
Market Capitalization
$89.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Atossa Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$5.50
669.66% Upside
High Prediction$6.00
Average Prediction$5.50
Low Prediction$5.00
TypeCurrent
10/3/22 to 10/3/23
1 Month Ago
9/3/22 to 9/3/23
3 Months Ago
7/5/22 to 7/5/23
1 Year Ago
10/3/21 to 10/3/22
Consensus Rating
Buy
N/AN/AN/A
Strong Buy
0 Strong Buy rating(s)
N/A N/A N/A
Buy
1 Buy rating(s)
N/A N/A N/A
Hold
0 Hold rating(s)
N/A N/A N/A
Sell
0 Sell rating(s)
N/A N/A N/A
Consensus Price Target$5.50$6.00$6.00$7.00
Predicted Upside669.66% Upside645.34% Upside645.34% Upside593.07% Upside
Get Atossa Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.


ATOS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ATOS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Atossa Therapeutics Stock vs. The Competition

TypeAtossa TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside669.66% Upside842.51% Upside698.28% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/8/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$5.00+572.49%
11/16/2022Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$6.00+645.33%
(Data available from 10/3/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ATOS Price Target - Frequently Asked Questions

What is Atossa Therapeutics's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Atossa Therapeutics stock is Buy based on the current 1 buy rating for ATOS. The average twelve-month price prediction for Atossa Therapeutics is $5.50 with a high price target of $6.00 and a low price target of $5.00. Learn more on ATOS's analyst rating history.

Do Wall Street analysts like Atossa Therapeutics more than its competitors?

Analysts like Atossa Therapeutics more than other Medical companies. The consensus rating for Atossa Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how ATOS compares to other companies.

Does Atossa Therapeutics's stock price have much upside?

According to analysts, Atossa Therapeutics's stock has a predicted upside of 619.90% based on their 12-month price targets.

What analysts cover Atossa Therapeutics?

Atossa Therapeutics has been rated by Cantor Fitzgerald in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ATOS) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -